Condition
Diffuse Large B-cell Lymphoma(DLBCL)
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Terminated1
Recruiting1
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06682130Phase 2RecruitingPrimary
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
NCT05189197Phase 2Active Not RecruitingPrimary
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression
NCT03571828Phase 1TerminatedPrimary
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Showing all 3 trials